VMP (Bortezomib, Melphalan, and Prednisone) Is Active and Well Tolerated in Newly Diagnosed Patients With Multiple Myeloma With Moderately Impaired Renal Function, and Results in Reversal of Renal Impairment: Cohort Analysis of the Phase III VISTA Study

JOURNAL ARTICLE published 20 December 2009 in Journal of Clinical Oncology

Authors: Meletios A. Dimopoulos | Paul G. Richardson | Rudolf Schlag | Nuriet K. Khuageva | Ofer Shpilberg | Efstathios Kastritis | Martin Kropff | Maria T. Petrucci | Michel Delforge | Julia Alexeeva | Rik Schots | Tamás Masszi | Maria-Victoria Mateos | William Deraedt | Kevin Liu | Andrew Cakana | Helgi van de Velde | Jesús F. San Miguel